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Abstract Ͷͻ 
Vaccines induce memory B-cells that provide high affinity secondary antibody ͷͲ 
responses to identical antigens. Memory B-cells can also re-instigate affinity ͷͳ 
maturation, but how this happens against antigenic variants is poorly understood ͷʹ 
despite its potential impact on driving broadly protective immunity against pathogens ͷ͵ 
such as Influenza and Dengue. We immunised mice sequentially with identical or ͷͶ 
variant Dengue-virus envelope proteins and analysed antibody and germinal-centre ͷͷ 
(GC) responses. Variant protein boosts induced GC with higher proportions of IgM+ ͷ͸ 
B-cells. The most variant protein re-stimulated GCs with the highest proportion of ͷ͹ 
IgM+ cells with the most diverse, least mutated V-genes and with a slower but ͷͺ 
efficient serum antibody response. Recombinant antibodies from GC B-cells showed ͷͻ 
a higher affinity for the variant antigen than antibodies from a primary response, ͸Ͳ 
confirming a memory origin. This reveals a new process of antibody memory, that ͸ͳ 
IgM memory cells with fewer mutations participate in secondary responses to variant ͸ʹ 
antigens, demonstrating how the hierarchical structure of B-cell memory is used and ͸͵ 
indicating the potential and limits of cross-reactive antibody based immunity. ͸Ͷ 
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Introduction ͹ͷ 
Antibody-based immunity is underpinned by memory B-cells that have undergone ͹͸ 
antibody somatic hyper-mutation (SHM) and selection for improved antigen binding ͹͹ 
in germinal centres (GCs) (MacLennan et al., 1997). Re-challenge with the same ͹ͺ 
antigen stimulates a rapid, higher affinity, secondary antibody response. ͹ͻ 
Protective immunity to highly mutable viruses, like Dengue and Influenza, can ͺͲ 
be induced by vaccination but the high level of variation often leads to immune ͺͳ 
escape (Nabel & Fauci, 2010), leading to a focus on generating vaccine responses ͺʹ 
against conserved antigenic regions (Wu et al., 2010; Corti et al., 2011; Wang et al., ͺ͵ 
2015). ͺͶ 
Memory B-cells of IgM and IgG isotypes can also re-instigate GCs after ͺͷ 
secondary exposure (Dogan et al., 2009; Pape et al., 2011; McHeyzer-Williams et al., ͺ͸ 
2015), but how this happens against variant antigens is poorly understood despite its ͺ͹ 
potential impact on driving the most broadly protective immunity. ͺͺ 
Several studies suggest diversity in the memory B-cell population, showing ͺͻ 
that cells can express IgM or IgG (Dogan et al., 2009; Pape et al., 2011), be mutated ͻͲ 
or non-mutated (Kaji et al., 2012) and have low affinities (Smith et al., 1997), but still ͻͳ 
persist in GCs (Kuraoka et al., 2016).  ͻʹ 
It has long been speculated that this diversity may facilitate the recognition of ͻ͵ 
antigenic variants (Herzenberg et al., 1980; Pape et al., 2011; Kaji et al., 2012) which ͻͶ 
could stimulate secondary GCs derived from less mutated, naïve-like, memory B-cells ͻͷ 
that still had an advantage over naive B-cells due to their increased numbers, pre-ͻ͸ 
selected V-genes and lower activation thresholds (Good et al., 2007; Good et al., ͻ͹ 
2009).  ͻͺ 
 Ͷ
By sequentially immunizing mice with the same or different Dengue-virus ͻͻ 
envelope proteins, and analyzing serum antibodies and GC B-cells, we provide ͳͲͲ 
evidence that supports the hypothesis that less developed memory B-cells are used in ͳͲͳ 
secondary responses to variant antigens. ͳͲʹ 
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Results  ͳʹͶ 
E-protein variants elicit secondary serum antibody responses with different speed and ͳʹͷ 
cross-reactivity ͳʹ͸ 
We chose Dengue-3 envelope protein (E3) for all priming immunisations. Boost ͳʹ͹ 
immunisations were performed 38 days later with identical E3 protein or variant E2 or ͳʹͺ 
E4 proteins which have 68% and 63% overall sequence identity with E3, respectively. ͳʹͻ 
The cross reactivity of E3-primed mouse serum IgG correlated with sequence ͳ͵Ͳ 
identity (Fig. 1A), and overall cross-reactivity also correlated (Fig 1B). ͳ͵ͳ 
Boosting with homotypic E3 antigen induced a rapid antibody memory ͳ͵ʹ 
response with anti-E3 titres rising rapidly to day 7, and not increasing further (Fig ͳ͵͵ 
1D). E-protein boosted antisera was not reactive with an irrelevant His-tagged protein ͳ͵Ͷ 
(PR8 HA)(Fig 1C). ͳ͵ͷ 
Heterotypic boosting with E2 induced a rapid and significant increase in anti-ͳ͵͸ 
E3 titre, as might be expected if cross-reactive memory antibodies against the priming ͳ͵͹ 
E3 antigen were recalled (Figure 1D), that did not increase further by day 17. E4 ͳ͵ͺ 
boosting induced a modest but not statistically significant increase in the anti-E3 titre, ͳ͵ͻ 
even by day 17, showing the E4 variant boost had not induced a significant anti-E3 ͳͶͲ 
antibody memory response, or the induced antibodies had a low affinity for E3 (see ͳͶͳ 
discussion).  ͳͶʹ 
The anti-E2 titre induced by the E2 boost increased about 120-fold by day 7 ͳͶ͵ 
(Figure 1E), and did not increase further by day 17, further indicating that E2 boosting ͳͶͶ 
induced a rapid memory-like serum IgG response against E2 derived from cross-ͳͶͷ 
reactive E3 primed memory B-cells. Conversely the anti-E4 titre, induced by E4 ͳͶ͸ 
boosting, rose significantly but to a lower level, about 20-fold, by day 7 (Figure 1F) ͳͶ͹ 
and showed a further rise by day 17. A boost alone did not induce a detectable ͳͶͺ 
 ͸
antibody titre however, (‘BO’, Figure 1D) suggesting a role for memory B-cells of ͳͶͻ 
some type and/or cross-reactive T-cell memory, facilitating the E4 boost response. ͳͷͲ 
 ͳͷͳ 
Increased levels of IgM+ GC B-cells with fewer mutations after variant protein ͳͷʹ 
boosting ͳͷ͵ 
E3 and E2 boosting induced early GC B-cell levels similarly by day 7, to 4.5-5.5% of ͳͷͶ 
total lymphocytes, which then reduced by two-thirds by day 17 (Figure 2B). E4 ͳͷͷ 
boosting induced GC B-cell levels about a third as high, which then reduced similarly ͳͷ͸ 
by about 60% at day 17, remaining 4-fold higher than controls.  ͳͷ͹ 
Analysis of the proportion of IgM+ GC B-cells showed a highly significant ͳͷͺ 
trend at day 7 after boosting, with the proportion of IgM+ GC B-cells correlating with ͳͷͻ 
increasingly variant challenge (Figure 2C). This trend continued to day 17. The ͳ͸Ͳ 
proportion of IgM+ B-cells was also consistent between individuals in an ͳ͸ͳ 
experimental group (Figure 2D). ͳ͸ʹ 
Overall levels of VH mutations increased in all groups from day 7 to day 17 ͳ͸͵ 
(Figure 2E), consistent with secondary affinity maturation. Sequences are available in ͳ͸Ͷ 
Supplementary File 1. ͳ͸ͷ 
There were lower levels of SHM in IgM+ GC B-cells 7 days after the variant ͳ͸͸ 
boosts, particularly with the most variant protein E4, compared to the homotypic E3 ͳ͸͹ 
boost (Figure 2F). Boosting with variant proteins, therefore, induced early GCs with ͳ͸ͺ 
increased proportions of IgM B-cells that had fewer VH mutations.  ͳ͸ͻ 
Analysis of the VH clonality of GC B-cells after E-protein boosts showed that ͳ͹Ͳ 
almost every VH sequence was from a distinct B-cell clone (Figure 2G). These data ͳ͹ͳ 
also showed that the two variant boosts elicited different repertoires of VH. 40% of ͳ͹ʹ 
the VH sequences sampled at day 7 from E2 boosted mice were either VH14-3 or the ͳ͹͵ 
 ͹
closely related VH14-4 (black dots, Figure 2G), suggestive of a secondary response ͳ͹Ͷ 
more focused on a particular epitope (see discussion)  Some of these VH were also ͳ͹ͷ 
present in the homotypic E3 boost day 7 samples. but neither were detected at day 7 ͳ͹͸ 
after E4 boosting (Figure 2G). ͳ͹͹ 
 ͳ͹ͺ 
Changes in serum affinity/avidity after variant antigen boosting ͳ͹ͻ 
E2-variant boosting induced an immediate and significant increase in avidity by day 7 ͳͺͲ 
(Figure 3A) which did not detectably change until perhaps day 32, although data ͳͺͳ 
variability is high. A modest but significant increase in serum affinity, however, was ͳͺʹ 
detected by day 17, with a further increase detected by day 32 (Figure 3C). We ͳͺ͵ 
interpret this to mean that a relatively small portion of serum IgG underwent affinity ͳͺͶ 
maturation by day 17 in response to the E2 boost and was not detectable by the Urea ͳͺͷ 
avidity assay due to high variability and the high pre-existing IgG titres (Figure 1E), ͳͺ͸ 
or other limitations of the Urea assay (Alexander et al., 2015). Boosting with the E4 ͳͺ͹ 
variant elicited slower increases in relative affinity and avidity, only detectable by day ͳͺͺ 
32, but by then representing an equivalent, if not greater, increase compared to that ͳͺͻ 
induced by E2 (Figure 3B & 3D)..  ͳͻͲ 
 ͳͻͳ 
Similar memory T-cell stimulation by variant Dengue E-proteins ͳͻʹ 
Memory T-cells are necessary for memory B-cell responses against haptens and viral ͳͻ͵ 
proteins (Aiba et al., 2010; Hebeis et al., 2004). We found no evidence that the ͳͻͶ 
memory T-cell response to re-stimulation by variant E-proteins was any different ͳͻͷ 
from re-stimulation by E3 (Figure 3E). These data imply that a deficiency in T-cell ͳͻ͸ 
recognition of these antigens cannot explain the differences in response to E2 and E4 ͳͻ͹ 
challenge, and supports the idea that either T-cell receptors can recognize antigenic ͳͻͺ 
peptides from regions with around 50% sequence difference (see discussion) or, more ͳͻͻ 
 ͺ
likely, B-cells present peptides from different, more conserved regions than those ʹͲͲ 
their antibodies bind to. ʹͲͳ 
 ʹͲʹ 
The primary antibody and GC response to E4 ʹͲ͵ 
For comparison with the E4 boost response, we performed primary immunisations ʹͲͶ 
with E4 and analysed serum antibodies and GC B-cells at day 7 and day 17. Serum ʹͲͷ 
levels of anti-E4 IgG rose to a moderate level by day 17 (mean EPT = 3.6, Figure ʹͲ͸ 
4A), being less than seen after E4 boosting (Figure 1F). GC B-cell levels rose to a ʹͲ͹ 
mean of 0.8% lymphocytes at day seven after E4 priming, half as much as after the E4 ʹͲͺ 
boost, then fell similarly to the post boost samples by around 60% by day 17 (Figure ʹͲͻ 
4B). As with the E-boost GCs, the proportion of IgM+ GC B-cells fell over time ʹͳͲ 
(Figure 4C) and levels of VH mutation in all B-cells and IgM+ B-cells increased ʹͳͳ 
(Figure 4D & 4E). The median level of VH mutation in IgM+ GC B-cells at day 7 ʹͳʹ 
after E4 priming is less (=2) than after E4 boosting (=3) suggesting, not conclusively, ʹͳ͵ 
that GC Bells at day 7 after E4 boosting are memory derived. Antibody titres were ʹͳͶ 
insufficient to do a relative affinity competition ELISA and no 7M Urea resistant IgG ʹͳͷ 
was detected 7 or 17 days after E4 priming (data not shown). ʹͳ͸ 
 ʹͳ͹ 
IgM Antibodies from E4 boost GC show evidence of prior selection ʹͳͺ 
If E4 boost induced B-cells are memory derived the antibodies should show evidence ʹͳͻ 
of pre-selection by the E3 prime. We made 48 recombinant antibodies (rAbs), 38 of ʹʹͲ 
which were IgM (supplementary file 2), 24 from E4 primed mice (day 7 and day 17) ʹʹͳ 
and 24 from E4 boosted mice (day 7). Figure 4F and Supplementary File 2, show the ʹʹʹ 
results from the initial screen of all rAbs against E4, indicating that the efficiency of ʹʹ͵ 
detection of positive binding (deemed as O.D. > 0.1, useful for subsequent titration) ʹʹͶ 
 ͻ
was quite low but consistent with the 30-50% binding frequency of GC rAbs ʹʹͷ 
previously observed (Kuraoka et al., 2016), except for E4 prime day 7, which has only ʹʹ͸ 
2/13 rAbs binding strongly enough to be titrated. This might be expected of antibodies ʹʹ͹ 
from a day 7 primary response GC, and indicated they were overall of lower affinity. ʹʹͺ 
Other rAbs from this group showed evidence of weak binding (supplementary file 2), ʹʹͻ 
indicating that the rAb cloning efficiency for this group was not reduced and only the ʹ͵Ͳ 
two strongest binders were above the ELISA titration threshold. All but one of the ʹ͵ͳ 
positive binding rAbs were IgM. Figure 4G shows the ELISA titration and Figure 4H ʹ͵ʹ 
the derived endpoint titres, which we are using as a proxy of affinity. A more strongly ʹ͵͵ 
binding IgM rAb from E4 boost day 7, B5, and the only positive binding IgG1 rAb, ʹ͵Ͷ 
G6, are indicated on Figure 4H. The positive-binding rAbs from E4 prime day 17 ʹ͵ͷ 
show a higher affinity than those from prime day 7, consistent with affinity ʹ͵͸ 
maturation. Six of the seven positive-binding IgM rAbs from E4 boost day 7 show a ʹ͵͹ 
higher affinity than the two strongest binding IgM rAbs from E4 prime day 7. This is ʹ͵ͺ 
consistent with pre-selection by the E3 prime immunization, and also considering the ʹ͵ͻ 
higher proportion of rAbs with an anti-E4 O.D. > 0.1, implies the GC B-cells ʹͶͲ 
expressing these antibodies are memory derived. rAb affinities were generally low, ʹͶͳ 
which might be expected of IgMs particularly in early GCs. We estimated the Kd of ʹͶʹ 
rAbs B5 and G6 (an IgG1) as around 150nm and 1μm respectively (see Methods). ʹͶ͵ 
Other rAbs would be in the super-micromolar range. Figure 4I shows the cross ʹͶͶ 
reactivity of rAbs with E3. Binding to E3 correlates with binding to E4, but because ʹͶͷ 
of the generally low rAb affinities we suggest that the  antibodies cannot discriminate ʹͶ͸ 
between similar epitopes. The higher affinity of E4 boost rAbs B5 and G6, and ʹͶ͹ 
binding to E3, suggest they may have genuine specificity for E3, thus consistent with ʹͶͺ 
 ͳͲ
their derivation from anti-E3 memory. That rAb B5 is an IgM with only one VH (and ʹͶͻ 
one Vkappa) mutation, provides further support for the proposal of this study. ʹͷͲ 
 ʹͷͳ 
Discussion ʹͷʹ 
The most variant protein we boosted with, E4, stimulated GCs with the highest ʹͷ͵ 
proportion of IgM+ cells and with the lowest levels of VH gene mutation, greater VH-ʹͷͶ 
gene diversity, and a slower, more specific, serum IgG response that resulted in ʹͷͷ 
equivalent if not higher affinity, compared to the heterotypic E2 boost.  This response ʹͷ͸ 
was higher than the primary response to E4. IgM rAbs cloned from E4 boost day 7 ʹͷ͹ 
GC showed a higher affinity for E4 than those from E4 primed day 7 GC, implying ʹͷͺ 
they were memory derived. This demonstrates that IgM memory cells with fewer ʹͷͻ 
mutations, from ‘lower’ levels of the memory compartment, participate in secondary ʹ͸Ͳ 
responses to variant antigens, and further challenges the hypothesis that highly ʹ͸ͳ 
mutated, class-switched cells elicited by homotypic antigen boosting are a ‘mirror’ of ʹ͸ʹ 
the antibody memory compartment (Weiss & Rajewsky, 1990). The slower nature of ʹ͸͵ 
the E4 boost response also suggests a lower level of immediate differentiation of ʹ͸Ͷ 
memory cells into AFCs than seen with for example the homotypic or E2 response, ʹ͸ͷ 
and is consistent with reduced numbers of high affinity class-switched memory cells ʹ͸͸ 
recognizing E4.   ʹ͸͹ 
 The serum antibody response to the closer variant, E2, was more rapid, more ʹ͸ͺ 
cross-reactive and evidenced some earlier affinity maturation. These observations are ʹ͸ͻ 
consistent with a response derived more from the ‘higher’ layers of the E3 specific ʹ͹Ͳ 
memory compartment. The IgM+ cells induced by E2 boosting have more mutations ʹ͹ͳ 
than after E4 boosting, indicating they are memory derived. As there are higher ʹ͹ʹ 
proportions of these IgM+ GC B-cells, with fewer mutations relative to the homotypic ʹ͹͵ 
 ͳͳ
E3 boost, this provides further support for the hypothesis that IgM+ B-cells with ʹ͹Ͷ 
fewer mutations furnish memory responses to variant antigens  ʹ͹ͷ 
Naïve B-cells may contribute to the IgM+ GC B-cells we observe after E4 ʹ͹͸ 
boosting, although the higher affinities of the rAbs from this group suggest many are ʹ͹͹ 
memory derived. Also, the slightly higher median level of VH mutation and the ʹ͹ͺ 
higher levels of IgM+ GC B-cells after E4 boosting (2x) compared to priming, ʹ͹ͻ 
suggest IgM+memory B-cells are involved in the boost response consistent with the ʹͺͲ 
well established presence of IgM+ memory cells with few or no mutations (Dogan et ʹͺͳ 
al., 2009; Pape et al. 2011; Kaji et al., 2012) and the known lower activation threshold ʹͺʹ 
of memory B-cells in response to antigen (Good et al., 2007 & 2009).  ʹͺ͵ 
Whilst E3 specific memory cells may be expected to increase the anti-E3 titre ʹͺͶ 
when stimulated by a cross-reactive E4 boost, the small but not significant effect we ʹͺͷ 
observe (Figure 1D) is consistent with the lowest affinity, least mutated, E3-specific ʹͺ͸ 
memory cells being stimulated by an E4 boost. Antibodies from such cells may, ʹͺ͹ 
therefore not add much to the already high, affinity matured, anti-E3 titre induced by ʹͺͺ 
E3 priming. The 14-fold higher anti-E4 titre at day 7 after boost (Figure 1F) versus ʹͺͻ 
day 17 after prime (Figure 4A) also argues for a significant contribution from B-cell ʹͻͲ 
memory.  ʹͻͳ 
The fusion-loop epitope in domain 2 of the dengue envelope protein is 100% ʹͻʹ 
conserved between strains and in humans, antibodies against this are prevalent in ʹͻ͵ 
cross-reactive secondary responses (Lai et al, 2013, Chaudhury et al., 2017). The E2 ʹͻͶ 
boost response is consistent with this effect, especially considering the restricted ʹͻͷ 
clonality seen in VH sequences, but the low anti-E3 titre induced by E4 is not. A ʹͻ͸ 
recent study (Chaudhury et al. 2017) showed that the mouse response to recombinant ʹͻ͹ 
E-protein is predominantly focused on domain 3 of the protein, and so cross reactivity ʹͻͺ 
 ͳʹ
with the fusion loop epitope (domain 2) should be less dominant. While E2 and E4 are ʹͻͻ 
68% and 63% overall identical to E3, in domain 3, a focus of mouse antibodies, they ͵ͲͲ 
are 62% and 51% identical, a bigger difference in differences, helping explain the ͵Ͳͳ 
responses we observe here.  ͵Ͳʹ 
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Materials and Methods ͵ʹ͸ 
Animals, immunisations and antigens ͵ʹ͹ 
Female 8-11-week old BALB/c mice were purchased from Charles River, U.K. ͵ʹͺ 
Primary immunisations were intra-peritoneal (IP) with 25μg recombinant Dengue ͵ʹͻ 
envelope protein (Biorbyt) precipitated in alum with 2x107 heat-killed B.pertussis. ͵͵Ͳ 
Secondary immunisations were IP with 25μg recombinant Dengue envelope protein ͵͵ͳ 
(Biorbyt) dissolved in phosphate-buffered saline (PBS). At designated time points ͵͵ʹ 
mice were anaesthetized and bled for collection of serum and then humanely ͵͵͵ 
sacrificed for collection of spleen cells. Dengue envelope (E) proteins were C-͵͵Ͷ 
terminal His-tagged and expressed in E-coli prior to purification. Dengue proteins ͵͵ͷ 
were tested for endotoxin by LAL assay (Fisher Scientific) and contained it at a low ͵͵͸ 
level: E2, 5.4EU/μg; E3, 2.5EU/μg; E4, 3.1EU/μg. Endotoxin in this range does not ͵͵͹ 
give a detectable physiological response in mice (Copeland et al., 2005).  ͵͵ͺ 
 ͵͵ͻ 
ELISA for serum and rAbs ͵ͶͲ 
ELISA plates (Nunc Maxisorp) were coated overnight at 4OC with 1μg/ml protein in ͵Ͷͳ 
0.1M bicarbonate buffer pH 9.3. Plates were washed three times in PBS/0.05% ͵Ͷʹ 
Tween-20 (Sigma) (PBST) and blocked for 30mins at room temperature with ͵Ͷ͵ 
PBST/2% bovine serum albumin (BSA, Sigma). Plates were then washed three times ͵ͶͶ 
and incubated with serum dilutions in PBST/1.0% BSA for two hours at room ͵Ͷͷ 
temperature. After three washes plates were incubated with alkaline-phosphatase ͵Ͷ͸ 
conjugated goat anti-mouse IgG (Sigma) for one hour at room-temperature, washed ͵Ͷ͹ 
three times and developed with pNPP substrate (Sigma) for one hour. Absorbance ͵Ͷͺ 
 ͳͶ
was measured at 405nm. For the initial rAb screen, rAbs were incubated at 100μgml-1 ͵Ͷͻ 
in PBST/1.0% BSA for 2 hours at room temperature on plates coated with E4 and ͵ͷͲ 
blocked as above, and subsequently treated as above except with use of anti-human ͵ͷͳ 
IgG second layer (Sigma). Background binding to plates was determined using ͵ͷʹ 
binding of non-specific polyclonal human IgG at 100μgml-1, because the rAbs were ͵ͷ͵ 
expressed as chimeric constructs with human constant regions, and this was ͵ͷͶ 
subtracted from the rAb O.D. Positive binding rAbs were deemed to be those with ͵ͷͷ 
O.D. > 0.1 that could be subject to an ELISA endpoint titration. For the ELISA ͵ͷ͸ 
titration and endpoint analysis, doubling dilutions of positive binding rAbs, and ͵ͷ͹ 
polyclonal IgG background subtraction control, were used starting at 100μgml-1. ͵ͷͺ 
Endpoint titre was set at O.D. = 0.1 and calculated using interpolation on Graphpad ͵ͷͻ 
Prism. The assay was repeated using E3 coated plates to determine the rAB cross ͵͸Ͳ 
reactivity. The affinity (Kd) of rAbs B5 and G6 (the two strongest binding rAbs) was ͵͸ͳ 
estimated from the inflection point of the ELISA titration curve as indicating 50% ͵͸ʹ 
maximal binding, and on the assumption that at these higher antibody concentrations ͵͸͵ 
binding of rAB to immobilized antigen will have a minor effect on concentration of ͵͸Ͷ 
unbound rAb. We estimated the B5 inflection point to be at approximately 25ugml-1 ͵͸ͷ 
(= approx. 150nM) and the G6 inflection point to be just above 100ugml-1 (= approx. ͵͸͸ 
1uM) ͵͸͹ 
 ͵͸ͺ 
Competition ELISA ͵͸ͻ 
ELISA plates were coated as above with target protein, then washed, blocked and ͵͹Ͳ 
washed as above except the blocking was done at 37OC for one hour. Mouse serum ͵͹ͳ 
samples were diluted in PBST/1% BSA to twice the concentration of the maximum ͵͹ʹ 
dilution that gave an absorbance at 405nm =1.0 in ELISA to the target protein. Serial ͵͹͵ 
 ͳͷ
six-fold dilutions of competitor protein were made in PBST/1% BSA, such that the ͵͹Ͷ 
highest concentration of competitor was 2.4μg in 30μl. 30μl of diluted serum was ͵͹ͷ 
mixed with 30μl of each competitor protein dilution and incubated in a polypropylene ͵͹͸ 
96-well plate at 37OC for 1 hour. Serum/competing antigen mixture (50μl) was then ͵͹͹ 
added to each well of the target antigen coated plate and incubated at 37OC for one ͵͹ͺ 
hour. Plates were washed as above and then 50μl of alkaline–phosphatase conjugated ͵͹ͻ 
anti-mouse IgG (Sigma) was added to each well followed by incubation at 37OC for ͵ͺͲ 
one hour. Plates were washed as above and incubated with 75μl per well of p-͵ͺͳ 
nitrophenyl phosphate substrate (Sigma) for one hour at room temperature. ͵ͺʹ 
Absorbance was measured at 405nm. All individual serum dilutions were also reacted ͵ͺ͵ 
in the absence of competitor, against BSA, following the same incubation protocol. ͵ͺͶ 
These background values were subtracted from the competition ELISA values ͵ͺͷ 
obtained above. The readings were then normalized so that the samples with the ͵ͺ͸ 
maximum competitor dilution gave a value of 1.0 ͵ͺ͹ 
 ͵ͺͺ 
Urea Avidity ELISA ͵ͺͻ 
Adapted from Puschnik et al., 2013. Assay plates were coated with antigen and ͵ͻͲ 
blocked as for the ELISA protocol. 1/200 dilutions of serum in PBST/1% BSA were ͵ͻͳ 
incubated on plates for 2 hours at room temperature. Wells were washed once with ͵ͻʹ 
PBST, incubated for 10 minutes at room temperature with PBST or PBST/7M Urea, ͵ͻ͵ 
washed a further two times with PBST and then treated as for standard ELISA. The ͵ͻͶ 
avidity index was calculated by dividing readings from 7M Urea treatment by ͵ͻͷ 
readings from PBST-only treatment, after subtraction of background absorbance. ͵ͻ͸ 
 ͵ͻ͹ 
 ͳ͸
Flow cytometry ͵ͻͺ 
Whole spleen cell-suspensions were red-cell depleted with Pharm-Lyse (BD ͵ͻͻ 
Biosciences) and incubated with anti-CD16/32 monoclonal antibody (Fc-block, BD ͶͲͲ 
Biosciences) for 15minutes at 4OC. Cells were then stained with APC anti-B220, ͶͲͳ 
BV421 anti-CD38, PE anti-CD95/Fas (all BD) and FITC anti-IgM (eBioscience) for ͶͲʹ 
45 minutes at 4OC. After washing, cells were re-suspended in PBS 5% FCS (Gibco) ͶͲ͵ 
and analysed or single-cell sorted on a FACS Aria II (BD). ͶͲͶ 
 ͶͲͷ 
GC B-cell antibody sequencing, cloning, expression and purification ͶͲ͸ 
Single GC B-cells were sorted into half a 96 well PCR plate (less 3 control wells) ͶͲ͹ 
containing10μl of chilled 10mM Tris pH 8.0, 1U/μl RNAsin (Promega) and placed on ͶͲͺ 
dry ice then at -80OC. One-Step RT-PCR (Qiagen) was performed according to ͶͲͻ 
manufacturers instructions, by adding 15μl RT-PCR master mix, using first-round ͶͳͲ 
primer sets described in Tiller et al., 2009, with heavy-chain and kappa-chain primers, Ͷͳͳ 
for 50 cycles, annealing at 53.6OC. Heavy-chain second-round PCRs were performed Ͷͳʹ 
using 2μl first-round product and the nested/semi-nested primer sets from Tiller et al., Ͷͳ͵ 
2009, with Hot Star Taq polymerase (Qiagen) for 50 cycles annealing at 56OC. ͶͳͶ 
Second round PCR product (4μl) was analysed on a 1.2% agarose gel. Successful Ͷͳͷ 
PCRs were then Sanger sequenced. For this study the sequencing primer was the pan Ͷͳ͸ 
VH primer 5’MsVHE (Tiller et al., 2009) which leaves part of the 5’ of FR1 Ͷͳ͹ 
unsequenced. For this reason the FR1 sequence was not included in the analysis. VH Ͷͳͺ 
sequence identification and SHM analysis was done using the IMGT V-Quest online Ͷͳͻ 
platform. VH sequences are in Supplementary File 1. Further cloning, construction ͶʹͲ 
and expression of antibodies as chimeric IgG1 rAbs was done according to Tiller et Ͷʹͳ 
al., 2009. Briefly, second round PCRs of in-frame VH and VK sequences were Ͷʹʹ 
 ͳ͹
repeated with V-gene specific primers that included a restriction site for sub cloning Ͷʹ͵ 
(Tiller et al., 2009). These PCR products were purified (Qiagen), restriction digested, ͶʹͶ 
purified (Qiagen) and ligated (instant sticky-end ligase, NEB) into the appropriate Ͷʹͷ 
expression vector containing either human IgG1 or Kappa constant regions, prior to Ͷʹ͸ 
transformation into E. Coli NEB5-alpha (NEB). Expression constructs in transformed Ͷʹ͹ 
colonies were verified by sequence analysis prior to preparation of plasmid mini-Ͷʹͺ 
preps (Qiagen). 293A cells were split and grown to 80% confluence in DMEM with Ͷʹͻ 
ultra-low IgG FCS (PAN Biotech) in 150mm plates prior to replacement of medium Ͷ͵Ͳ 
with 20ml Panserin 293A serum free medium. 15ug each of matched VH and VKappa Ͷ͵ͳ 
constructs were added to 2ml saline with 90ug PEI, briefly vortexed and rested for Ͷ͵ʹ 
10mins. Transfection solution was added to plates and mixed gently. After 3 days Ͷ͵͵ 
medium was collected, centrifuged at 800g for 10mins to clear debris, and further Ͷ͵Ͷ 
medium added. After a further 3 days medium was collected, cleared of debris as Ͷ͵ͷ 
before and pooled. 100ul protein-G sepharose (GE Healthcare) was added to Ͷ͵͸ 
supernatants and incubated with rocking overnight at 4 OC. Protein G sepharose was Ͷ͵͹ 
collected by centrifugation at 800g for 10 mins and transferred in PBS to a PBS Ͷ͵ͺ 
equilibrated spin column (Bio-Rad). After 3 rounds of washing with 800ul of PBS, Ͷ͵ͻ 
rAbs were eluted in two 200ul passes of 0.1M Glycine (pH2.9) into a tube with 40ul ͶͶͲ 
of 1M Tris pH 8.0, 0.5% Sodium Azide. Antibody concentrations were determined by ͶͶͳ 
O.D. on a Nanodrop instrument (Thermo) and corrected for an extinction co-efficient ͶͶʹ 
of 1.36. ͶͶ͵ 
 ͶͶͶ 
T-cell proliferation assay  ͶͶͷ 
Spleens were harvested from female BALB/c AnCrl mice 39 days after challenge. ͶͶ͸ 
Splenocytes (5x105) were cultured in triplicate with the indicated concentration of E-ͶͶ͹ 
 ͳͺ
protein in X-VIVO 15 medium. Cells were cultured for 96 hours and 0.5 μCi of [3H] ͶͶͺ 
thymidine was added to wells for 16 hours before measurement with a 1450 ͶͶͻ 
MicroBeta counter (Wallac).  ͶͷͲ 
 Ͷͷͳ 
Statistics Ͷͷʹ 
For statistical analysis sample sizes were chosen to address group size reductions that Ͷͷ͵ 
observe the ARRIVE guidelines. Cages of three mice were randomly allocated to ͶͷͶ 
treatment groups. These group treatments were independently biologically replicated Ͷͷͷ 
to give a sample size of 6. Where statistical analysis was applied, data points were Ͷͷ͸ 
analysed with Levene’s test for equality of variance and where violated they were Ͷͷ͹ 
subject to a two-tailed Students t-test for unequal variance, otherwise the two-tailed t-Ͷͷͺ 
test for equal variance. Ͷͷͻ 
 Ͷ͸Ͳ 
 Ͷ͸ͳ 
 Ͷ͸ʹ 
 Ͷ͸͵ 
Acknowledgements Ͷ͸Ͷ 
We are especially grateful to the late Michael Neuberger for critical discussion and Ͷ͸ͷ 
early comment on the project. Thanks to Patrick Wilson and Christian Busse for Ͷ͸͸ 
advice on single cell antibody PCR, Per Klasse for advice on antibody avidity assays, Ͷ͸͹ 
James Cresswell for advice on statistics, Kai Toellner for discussions and Jamie Ͷ͸ͺ 
Gilman for extra FACS work.  Ͷ͸ͻ 
 Ͷ͹Ͳ 
 Ͷ͹ͳ 
References Ͷ͹ʹ 
 ͳͻ
Aiba, Y. et al. (2010). Preferential localization of IgG memory B cells adjacent to contracted germinal Ͷ͹͵ 
centers. Proceedings of the National Academy of Sciences of the United States of America, 107(27), Ͷ͹Ͷ 
12192–7.  Ͷ͹ͷ 
 Ͷ͹͸ 
Alexander, M. R., Ringe, R., Sanders, R. W., Voss, J. E., Moore, J. P., & Klasse, J. (2015). What Do Ͷ͹͹ 
Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure ?, J. Virol Ͷ͹ͺ 
89(11), 5981–5995. Ͷ͹ͻ 
Chaudhury, S., Gromowski, G. D., Ripoll, D. R., Khavrutskii, I. V, Desai, V., & Wallqvist, A. (2017). ͶͺͲ 
Dengue virus antibody database : Systematically linking serotype-specificity with epitope mapping in Ͷͺͳ 
dengue virus, PLoS Neg Trop Dis, 11,1–17.  Ͷͺʹ 
 Ͷͺ͵ 
Copeland, S., Warren, H. S., Lowry, S. F., Calvano, S. E., & Remick, D. (2005). Acute inflammatory ͶͺͶ 
response to endotoxin in mice and humans. Clinical and Diagnostic Laboratory Immunology, 12(1), Ͷͺͷ 
60–67.  Ͷͺ͸ 
 Ͷͺ͹ 
Corti, D. et al. (2011). A neutralizing antibody selected from plasma cells that binds to group 1 and Ͷͺͺ 
group 2 influenza A hemagglutinins. Science (New York, N.Y.), 333(6044), 850–6. Ͷͺͻ 
 ͶͻͲ 
Dogan, I., Bertocci, B., Vilmont, V., Delbos, F., Mégret, J., Storck, S., Reynaud, C-A. & Weill, J.-C. Ͷͻͳ 
(2009). Multiple layers of B cell memory with different effector functions. Nature Immunology, 10(12), Ͷͻʹ 
1292–1299 Ͷͻ͵ 
 ͶͻͶ 
Gitlin, A. D., Boehmer, L. Von, Gazumyan, A., Shulman, Z., Oliveira, T. Y. & Nussenzweig, M. C., Ͷͻͷ 
(2016). Independent Roles of Switching and Hypermutation in the Development and Persistence of B Ͷͻ͸ 
Lymphocyte Memory Article Independent Roles of Switching and Hypermutation in the Development Ͷͻ͹ 
and Persistence of B Lymphocyte Memory, 1–13. Ͷͻͺ 
 Ͷͻͻ 
Good, K. L., Avery, D. T., & Tangye, S. G. (2009). Resting Human Memory B Cells Are Intrinsically ͷͲͲ 
Programmed for Enhanced Survival and Responsiveness to Diverse Stimuli Compared to Naive B ͷͲͳ 
Cells. The Journal of Immunology, 182(2), 890–901.  ͷͲʹ 
 ͷͲ͵ 
Good, K. L., & Tangye, S. G. (2007). Decreased expression of Kruppel-like factors in memory B cells ͷͲͶ 
induces the rapid response typical of secondary antibody responses. Proceedings of the National ͷͲͷ 
Academy of Sciences of the United States of America, 104(33), 13420–13425.  ͷͲ͸ 
 ͷͲ͹ 
Hebeis, B. J., Klenovsek, K., Rohwer, P., Ritter, U., Schneider, A., Mach, M., & Winkler, T. H. (2004). ͷͲͺ 
Activation of virus-specific memory B cells in the absence of T cell help. The Journal of Experimental ͷͲͻ 
Medicine, 199(4), 593–602. http://doi.org/10.1084/jem.20030091 ͷͳͲ 
 ͷͳͳ 
 ʹͲ
Herzenberg, L. A, Black, S. J., & Tokuhisa, T. (1980). Memory B cells at successive stages of ͷͳʹ 
differentiation. Affinity maturation and the role of IgD receptors. The Journal of Experimental ͷͳ͵ 
Medicine, 151(5), 1071–87.  ͷͳͶ 
 ͷͳͷ 
Kaji, T. et al. (2012). Distinct cellular pathways select germline-encoded and somatically mutated ͷͳ͸ 
antibodies into immunological memory. The Journal of Experimental Medicine, 209(11), 2079–97.  ͷͳ͹ 
 ͷͳͺ 
Kometani, K. et al. (2013). Repression of the Transcription Factor Bach2 Contributes to Predisposition ͷͳͻ 
of IgG1 Memory B Cells toward Plasma Cell Differentiation. Immunity, 39(1), 136–147.  ͷʹͲ 
 ͷʹͳ 
Kuraoka, M., Schmidt, A. G., Nojima, T., Feng, F., Watanabe, A., Kitamura, D., Harrison, S. C., ͷʹʹ 
Kepler, T. B. & Kelsoe, G. (2016). Complex Antigens Drive Permissive Clonal Selection in Germinal ͷʹ͵ 
Centers. Immunity, 1–11. ͷʹͶ 
 ͷʹͷ 
Lai, C. Y., Williams, K. L., Wu, Y. C., Knight, S., Balmaseda, A., Harris, E., & Wang, W. K. (2013). ͷʹ͸ 
Analysis of Cross-Reactive Antibodies Recognizing the Fusion Loop of Envelope Protein and ͷʹ͹ 
Correlation with Neutralizing Antibody Titers in Nicaraguan Dengue Cases. PLoS Neglected Tropical ͷʹͺ 
Diseases, 7(9), 1–11. ͷʹͻ 
 ͷ͵Ͳ 
MacLennan, I. C., Gulbranson-Judge, A., Toellner, K. M., Casamayor-Palleja, M., Chan, E., Sze, D. ͷ͵ͳ 
M., Luther, S. A. & Orbea, H. A. (1997). The changing preference of T and B cells for partners as T-ͷ͵ʹ 
dependent antibody responses develop. Immunological Reviews, 156, 53–66.  ͷ͵͵ 
 ͷ͵Ͷ 
 ͷ͵ͷ 
McHeyzer-Williams, L. J., Milpied, P. J., Okitsu, S. L., & McHeyzer-Williams, M. G. (2015). Class-ͷ͵͸ 
switched memory B cells remodel BCRs within secondary germinal centers. Nature Immunology, ͷ͵͹ 
16(3), 296–305.  ͷ͵ͺ 
 ͷ͵ͻ 
Nabel, G. J., & Fauci, A. S. (2010). Induction of unnatural immunity: prospects for a broadly protective ͷͶͲ 
universal influenza vaccine. Nature Medicine, 16(12), 1389–1391.  ͷͶͳ 
 ͷͶʹ 
Pape, K. A., Taylor, J. J., Maul, R. W., Gearhart, P. J., & Jenkins, M. K. (2011). Different B cell ͷͶ͵ 
populations mediate early and late memory during an endogenous immune response. Science (New ͷͶͶ 
York, N.Y.), 331(6021), 1203–7.  ͷͶͷ 
Puschnik, A., Lau, L., Cromwell, E. A., Balmaseda, A., Zompi, S., & Harris, E. (2013). Correlation ͷͶ͸ 
between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary ͷͶ͹ 
Dengue Virus 3 Natural Infections in Humans, 7(6), 1–8. ͷͶͺ 
 ͷͶͻ 
 ʹͳ
Smith, K. G. C., Light, A., Nossal, G. J. V, & Tarlinton, D. M. (1997). The extent of affinity ͷͷͲ 
maturation differs between the memory and antibody-forming cell compartments in the primary ͷͷͳ 
immune response. EMBO Journal, 16(11), 2996–3006.  ͷͷʹ 
 ͷͷ͵ 
Tiller, T., Busse, C. E., & Wardemann, H. (2009). Cloning and expression of murine Ig genes from ͷͷͶ 
single B cells. Journal of Immunological Methods, 350(1–2), 183–193.  ͷͷͷ 
 ͷͷ͸ 
Toellner, K. M., Gulbranson-Judge, a, Taylor, D. R., Sze, D. M., & MacLennan, I. C. (1996). ͷͷ͹ 
Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B ͷͷͺ 
cell activation. The Journal of Experimental Medicine, 183(5), 2303–2312.  ͷͷͻ 
 ͷ͸Ͳ 
Victora, G. D. (2014). SnapShot: The Germinal Center Reaction. Cell, 159(3), 700–700. ͷ͸ͳ 
 ͷ͸ʹ 
Wang, S., Mata-Fink, J., Kriegsman, B., Hanson, M., Irvine, D. J., Eisen, H. N., Burton, D. R., Dane ͷ͸͵ 
Wittrup, K., Kardar, M. & Chakraborty, A. K. (2015). Manipulating the selection forces during affinity ͷ͸Ͷ 
maturation to generate cross-reactive HIV antibodies. Cell, 160(4), 785–797. ͷ͸ͷ 
 ͷ͸͸ 
Weiss, U., & Rajewsky, K. (1990). The repertoire of somatic antibody mutants accumulating in the ͷ͸͹ 
memory compartment after primary immunization is restricted through affinity maturation and mirrors ͷ͸ͺ 
that expressed in the secondary response. J Exp Med, 172(6), 1681–1689.  ͷ͸ͻ 
Wu, X. et al.. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal ͷ͹Ͳ 
antibodies to HIV-1. Science (New York, N.Y.), 329(5993), 856–861 ͷ͹ͳ 
 ͷ͹ʹ 
Figure Legends ͷ͹͵ 
 Figure 1 ͷ͹Ͷ 
Serum antibody responses after boosting with Dengue envelope protein variants ͷ͹ͷ 
A, Cross-reactivity of E3 primed serum IgG with E-protein variants. Red bar shows ͷ͹͸ 
mean value. Serum used was from mice mock-boosted with PBS 37 days after E3 ͷ͹͹ 
priming and obtained 7 days later; E3, Dengue-3 envelope protein; E2, Dengue-2 ͷ͹ͺ 
envelope protein; E4, Dengue-4 envelope protein; % identity, sequence identity ͷ͹ͻ 
between E3 envelope protein and respective protein; end-point titre (EPT) values ͷͺͲ 
plotted are log2 of 1/(end point dilution x 100), each unit increase represents a ͷͺͳ 
doubling of titre. B, E3 primed mouse serum cross-reactivity with E2 versus E4. C, ͷͺʹ 
 ʹʹ
Control. Anti-PR8 HA serum IgG titre of E3 day 7 boost serum. D, Anti-E3 serum ͷͺ͵ 
IgG titre after boosting with respective proteins. Red bar shows mean value. n=6 from ͷͺͶ 
two independent experiments for each group except boost only, n=3; first set of data ͷͺͷ 
points reproduced from panel A for comparison; numbers 3,2 and 4 refer to serotype ͷͺ͸ 
of Dengue-envelope protein used for boost; BO, adjuvant primed, E3 boosted, ͷͺ͹ 
analysed 7 days later; Day, days after boosting. p-values calculated using two-tailed ͷͺͺ 
Students t-test after testing for equality of variance. E, Anti-E2 serum IgG titre after ͷͺͻ 
E2 boost. Red bar shows mean value. n=6 from two independent experiments for each ͷͻͲ 
group; labeling and statistics as for panel D. F, Anti-E4 serum IgG titre after E4 ͷͻͳ 
boost. Red bar shows mean value. n=6 from two independent experiments for each ͷͻʹ 
group; labeling and statistics as for panel D. ͷͻ͵ 
 ͷͻͶ 
 ͷͻͷ 
 ͷͻ͸ 
 ͷͻ͹ 
Figure 2 ͷͻͺ 
GC B-cell levels, isotypes, VH mutation and clonality after boosting with E-ͷͻͻ 
protein variants ͸ͲͲ 
A, FACS gating strategy used to identify and sort GC B-cells and determine isotype. ͸Ͳͳ 
B, GC B-cell levels after E-variant boosting, expressed as % total lymphocytes; Red ͸Ͳʹ 
bar shows mean value; numbers 3,2 and 4 refer to serotype of Dengue-envelope ͸Ͳ͵ 
protein used for boost; BO, boost only, adjuvant primed, E3 boosted day 37, analysed ͸ͲͶ 
7 days later; Day, days after boosting. C, % IgM+ GC B-cells, of total GC B-cells, ͸Ͳͷ 
after boosting. Red bar shows mean value. n=6 from two independent experiments for ͸Ͳ͸ 
each group; labels as for panel B except % identity which refers to sequence identity ͸Ͳ͹ 
 ʹ͵
between E3 and other variants; p-values calculated using two-tailed Students t-test ͸Ͳͺ 
after testing for equality of variance. D, Levels of IgM+ and IgM- GC B-cells in ͸Ͳͻ 
individual boosted mice. E, Number of mutations detected in VH of all isotypes of ͸ͳͲ 
GC B-cells, from n=3 mice except E4 boost day 17, n=2. Red bar is median value. ͸ͳͳ 
VH region sequenced is CDR1 to FR3; labeling as panel B. F, Number of mutations ͸ͳʹ 
detected in VH of IgM+ GC B-cells, from n=3 mice except E4 boost day 17, n=2. Red ͸ͳ͵ 
bar is median value. G, Clonality of sequences from single GC B-cells 7 days after ͸ͳͶ 
boosting; colours indicate different mice in each group; thin sectors, unique ͸ͳͷ 
sequences; thicker sectors two or three clonal sequences according to sector size; ͸ͳ͸ 
black dots, VH 14-3 or VH14-4 sequences; numbers in circles, number of sequences ͸ͳ͹ 
from that mouse; Identical VH clones had the same: V-gene, CDR3 length, J-gene, D-͸ͳͺ 
gene if assigned, D-reading frame, three or fewer differences in CDR3 amino acid ͸ͳͻ 
sequence. ͸ʹͲ 
 ͸ʹͳ 
 ͸ʹʹ 
Figure 3 ͸ʹ͵ 
Relative serum affinity and avidity after boosting with E-protein variants, and ͸ʹͶ 
T-cell re-stimulation ͸ʹͷ 
A, Relative avidity of E2 boost serum for E2, measured by resistance to 7M Urea. ͸ʹ͸ 
Red bar shows mean value; Day, days after E2 boosting; Day 0 sample was from mice ͸ʹ͹ 
mock-boosted with PBS 37 days after priming with E3 and obtained 7 days later. B, ͸ʹͺ 
Relative avidity of E4 boost serum for E4, measured by resistance to 7M Urea. ͸ʹͻ 
Labeling as for panel A; Day 0 sample was from mice mock-boosted with PBS 37 ͸͵Ͳ 
days after priming with E3 and obtained 7 days later C, Relative affinity of E2 ͸͵ͳ 
boosted serum for E2. Inhibition by lower concentration of competitor implies higher ͸͵ʹ 
 ʹͶ
affinity of serum for competitor. Maximum competitor amount 2μg in 50μl followed ͸͵͵ 
by six-fold dilutions of competitor; timepoint of samples and numbers of individuals ͸͵Ͷ 
in group indicated. Open circles, E2 boost day 17 serum competed with irrelevant ͸͵ͷ 
His-tagged protein measured on E2 target D, Relative affinity of E4 boosted serum for ͸͵͸ 
E4. Labeling as for panel A. E, T-cell proliferation measured by 3H incorporation 96 ͸͵͹ 
hours after re-stimulation in vitro with indicated amounts of E-protein variants; error ͸͵ͺ 
bars indicate standard error of the mean; n=4 or 5 from two independent experiments ͸͵ͻ 
(see source data). Closed symbols, E3 primed mouse splenocytes re-stimulated with ͸ͶͲ 
indicated E-protein variant. Open symbols, adjuvant primed mouse splenocytes re-͸Ͷͳ 
stimulated with indicated E-protein variant. ͸Ͷʹ 
 ͸Ͷ͵ 
Figure 3 Source Data File ͸ͶͶ 
Source data for Figure 3 panels C, D and E ͸Ͷͷ 
 ͸Ͷ͸ 
 ͸Ͷ͹ 
Figure 4 ͸Ͷͺ 
Primary response to E4 and rAb binding. ͸Ͷͻ 
A, anti-E4 IgG titre after E4 priming; Red bars show mean titres; A, serum from ͸ͷͲ 
adjuvant-only primed mice at day 45; d7, 7 days after E4 priming; d17, 17 days after ͸ͷͳ 
E4 priming; EPT, end-point titre calculated as for Figure 1. B, GC B-cell levels after ͸ͷʹ 
E4 priming; Red bars indicate mean levels; A, cells from adjuvant-only primed mice 7 ͸ͷ͵ 
days after priming; other x-axis labels as for panel A. C, %IgM+ GC B-cells after E4 ͸ͷͶ 
priming; Red bars show mean values; x-axis labels as for panel A. D, Numbers of VH ͸ͷͷ 
mutations in all isotypes of GC B-cells after E4 priming; Red bars show median ͸ͷ͸ 
values, from n=3 mice (d7) and n=2 mice (d17); x-axis labels as for panel A. E, ͸ͷ͹ 
 ʹͷ
Numbers of VH mutations in IgM+ GC B-cells after E4 priming and boosting; Red ͸ͷͺ 
bars show median values, from n=3 mice (d7), n=2 mice (d17) and n=3 mice E4Bd7; ͸ͷͻ 
x-axis labels as for panel A except E4Bd7, 7 days after E4 boosting which was 38 ͸͸Ͳ 
days after E3 priming. F, ELISA screen of binding of all 48 rAbs. rAbs incubated at ͸͸ͳ 
100μgml-1. Number of rAbs in each group indicated. P7, 7days after E4 prime; P17, ͸͸ʹ 
17 days after E4 prime; B7, 7 days after E4 boost. As the antibodies were cloned as ͸͸͵ 
chimeric human IgG1 antibodies the background from non-specific human polyclonal ͸͸Ͷ 
IgG binding has been subtracted from O.D. readings. Values in supplementary file 2. ͸͸ͷ 
G, ELISA titration of rAbs that showed binding O.D. > 0.1 in panel F. All but one ͸͸͸ 
were IgM. IgG1 rAb indicated. Background subtraction as for panel F, using ͸͸͹ 
appropriate dilution of polyclonal IgG. H, Anti-E4 end point titre of positive-binding ͸͸ͺ 
rAbs, used as a proxy of rAB affinity. X-axis labels as for panel F. End-point titre ͸͸ͻ 
values plotted are log2 of 1/end point dilution (undiluted = 100μgml-1). Red bars show ͸͹Ͳ 
median values (excluding any IgG1 data). Stronger binding IgM rAb ‘B5’, and IgG1 ͸͹ͳ 
rAb ‘G6’ EPT readings indicated. I, anti-E3 versus anti-E4 endpoint titres. Star, E4 ͸͹ʹ 
prime day 7 rAbs; Square, E4 prime day 17 rAbs; circle, E4 boost day 7 rAbs. IgG1 ͸͹͵ 
EPT reading indicated. End-point titre values plotted are log2 of 1/end point dilution ͸͹Ͷ 
(undiluted = 100μgml-1). ͸͹ͷ 
 ͸͹͸ 
Supplementary File 1 ͸͹͹ 
GC B-cell VH Sequences ͸͹ͺ 
VH sequences from single sorted GC B-cells. Sequences are grouped into treatment ͸͹ͻ 
groups, and within this, arranged in blocks for sequences from individual mice. Raw ͸ͺͲ 
sequences were analysed by IMGT V-Quest. Due to cloning and sequencing primers ͸ͺͳ 
being at start of FR1 region, this region not included in mutation analysis. CDR1T, ͸ͺʹ 
 ʹ͸
total mutations in CDR1; CDR1S, silent mutations in CDR1; CDR1R, replacement ͸ͺ͵ 
mutations in CDR1; likewise for FR2, CDR2 and FR3 regions; Tot Mut, total ͸ͺͶ 
mutations in CDR1 to FR3 regions. ͸ͺͷ 
 ͸ͺ͸ 
Supplementary File 2 ͸ͺ͹ 
Data on recombinant antibodies ͸ͺͺ 
 ͸ͺͻ 
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